Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Cytokinetics Incorporated (KK3A) operate in?
Cytokinetics Incorporated belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cytokinetics Incorporated (KK3A) current stock price?
As of the latest data, Cytokinetics Incorporated stock price is €62.78, with a previous close of €63.14. Cytokinetics Incorporated lost -€0.36 in the last trading session, representing a -0.57% loss.
What is Cytokinetics Incorporated (KK3A) current market capitalization?
Cytokinetics Incorporated market cap is approximately 8.73 billion.
What is Cytokinetics Incorporated (KK3A) Earnings Per Share (EPS)?
The trailing EPS is -€6.23.
Does Cytokinetics Incorporated (KK3A) pay dividends?
No. Cytokinetics Incorporated does not pay a dividend.
When is Cytokinetics Incorporated (KK3A) next earnings report?
Cytokinetics Incorporated is expected to release its next earnings report on September 30, 2026.
What is Cytokinetics Incorporated (KK3A) beta (volatility) score?
Cytokinetics Incorporated has a beta of 0.360, indicating lower volatility than the overall market.
